GlassScriptPhysician profile
Kishor Bhende
NPI 1336304716
$972.49
in general payments reported to CMS, 2019-2025
19 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.96 · 2023: $363 · 2024: $308 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $145.00 | 2024 | Iwilfin |
| Genentech, INC. | $134.28 | 2024 | Hemlibra |
| Foundation Medicine, INC. | $125.00 | 2023 | Foundationone Cdx |
| Alexion Pharmaceuticals, INC. | $122.79 | 2023 | Koselugo |
| Genzyme Corporation | $90.31 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $53.40 | 2023-2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $47.25 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $36.55 | 2025 | |
| Day One Biopharmaceuticals | $36.03 | 2025 | Ojemda |
| Hema Biologics, LLC | $26.10 | 2025 | Sevenfact |
| Syndax Pharmaceuticals, INC. | $24.65 | 2025 | Revuforj |
| Daiichi Sankyo INC. | $22.86 | 2023 | Injectafer |
| Jazz Pharmaceuticals INC. | $17.71 | 2019 | |
| Amgen INC. | $16.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.07 | 2019 | |
| Pfizer INC. | $15.06 | 2025 | |
| Y-Mabs Therapeutics, INC. | $14.25 | 2023 | Danyelza |
| Silvergate Pharmaceuticals, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishor Bhende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.